Witnessing the stock’s movement on the chart, on Thursday, Dyne Therapeutics Inc (NASDAQ: DYN) had a quiet start as it plunged -5.14% to $23.69, before settling in for the price of $24.98 at the close. Taking a more long-term approach, DYN posted a 52-week range of $6.40-$30.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -106.26%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.30%. This publicly-traded company’s shares outstanding now amounts to $61.47 million, simultaneously with a float of $50.99 million. The organization now has a market capitalization sitting at $1.92 billion. At the time of writing, stock’s 50-day Moving Average stood at $26.00, while the 200-day Moving Average is $15.49.
Dyne Therapeutics Inc (DYN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Dyne Therapeutics Inc’s current insider ownership accounts for 37.13%, in contrast to 57.55% institutional ownership. According to the most recent insider trade that took place on Mar 12 ’24, this organization’s Chief Medical Officer sold 1,030 shares at the rate of 25.58, making the entire transaction reach 26,347 in total value, affecting insider ownership by 150,560. Preceding that transaction, on Mar 11 ’24, Company’s CEO & President sold 66,387 for 25.67, making the whole transaction’s value amount to 1,704,142. This particular insider is now the holder of 537,998 in total.
Dyne Therapeutics Inc (DYN) Earnings and Revenue Records
Dyne Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 16.30% and is forecasted to reach -3.26 in the upcoming year.
Dyne Therapeutics Inc (NASDAQ: DYN) Trading Performance Indicators
Let’s observe the current performance indicators for Dyne Therapeutics Inc (DYN). It’s Quick Ratio in the last reported quarter now stands at 2.53. The Stock has managed to achieve an average true range (ATR) of 1.58.
In the same vein, DYN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.94, a figure that is expected to reach -0.79 in the next quarter, and analysts are predicting that it will be -3.26 at the market close of one year from today.
Technical Analysis of Dyne Therapeutics Inc (DYN)
Going through the that latest performance of [Dyne Therapeutics Inc, DYN]. Its last 5-days volume of 0.82 million was inferior to the volume of 1.96 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 36.17% While, its Average True Range was 1.51.
Raw Stochastic average of Dyne Therapeutics Inc (DYN) in the period of the previous 100 days is set at 67.03%, which indicates a major rise in contrast to 12.47% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 47.46% that was lower than 82.15% volatility it exhibited in the past 100-days period.
